
Eli Lilly and Company LLY
$ 1 277.31
-0.56%
Eli Lilly and Company DPO Ratio | LLY
Annual DPO Ratio Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 142 | 126 | 117 | 99.1 | 81.8 | 100 | 109 | 80.2 | 84.8 | 87.1 | 97 | 83.5 | 83.2 | 90.4 | 81 | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 142 | 80.2 | 97.5 |
Quarterly DPO Ratio Eli Lilly and Company
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 156 | 119 | 126 | 140 | 130 | 122 | 113 | 134 | 120 | 113 | 111 | - | 48.6 | 45.7 | 68.3 | - | 101 | 75.6 | 78.8 | - | 111 | 120 | 113 | 100 | 109 | 114 | 105 | 97.5 | 95.5 | 89.2 | 94.6 | 101 | 111 | 113 | 131 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 156 | 45.7 | 106 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Завод ДИОД
DIOD
|
30.3 | - | - | - | ||
|
Фармсинтез
LIFE
|
306 | - | - | - | ||
|
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M | ||
|
Clearside Biomedical
CLSD
|
4.48 K | - | - | $ 25.3 M | ||
|
Cellectis S.A.
CLLS
|
975 | $ 0.95 | -3.3 % | $ 95.3 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
109 | $ 58.93 | 1.57 % | $ 7.88 B | ||
|
BioMarin Pharmaceutical
BMRN
|
245 | $ 55.62 | -0.59 % | $ 10.7 B | ||
|
Celldex Therapeutics
CLDX
|
4.06 K | $ 29.48 | 0.79 % | $ 1.96 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
323 | $ 3.75 | 2.18 % | $ 45.8 M | ||
|
Jaguar Health
JAGX
|
676 | $ 2.36 | 15.44 % | $ 5.5 M | ||
|
Protalix BioTherapeutics
PLX
|
66.2 | $ 2.49 | -2.35 % | $ 196 M | ||
|
uniQure N.V.
QURE
|
1.34 K | $ 21.65 | -3.5 % | $ 1.24 B | ||
|
Incyte Corporation
INCY
|
200 | $ 113.3 | -2.08 % | $ 22.1 B | ||
|
Mesoblast Limited
MESO
|
1.25 K | $ 12.43 | 1.22 % | $ 15 B | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
96.7 | $ 516.39 | -1.44 % | $ 132 B | ||
|
Catalyst Biosciences
CBIO
|
7.82 | $ 12.77 | -0.39 % | $ 1.14 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 25.47 | 1.29 % | $ 1.19 B | ||
|
Anika Therapeutics
ANIK
|
43.4 | $ 21.19 | -1.07 % | $ 304 M | ||
|
Evogene Ltd.
EVGN
|
62.6 | $ 0.37 | 0.44 % | $ 2.91 M | ||
|
EyePoint Pharmaceuticals
EYPT
|
302 | $ 0.36 | -10.09 % | $ 26.4 K | ||
|
Fortress Biotech
FBIO
|
400 | $ 1.87 | -3.11 % | $ 52.2 M | ||
|
Fennec Pharmaceuticals
FENC
|
894 | $ 10.12 | 0.4 % | $ 289 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
48.7 | $ 13.76 | 4.13 % | $ 11.5 B | ||
|
Sanofi
SNY
|
147 | $ 41.77 | 0.41 % | $ 51 B | ||
|
Arcutis Biotherapeutics
ARQT
|
133 | $ 31.74 | 1.73 % | $ 4.04 B | ||
|
Titan Pharmaceuticals
TTNP
|
1.88 K | - | -3.76 % | $ 3.47 M |